Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109279 | 0.84 | ALDH1A1 (0.67) | ALDH1A1GAAALOX12SMN1; SMN2TAAR1 | |
| SCHEMBL25990229 | 0.82 | ALDH1A1 (0.64) | ALDH1A1GAAALOX12SMN1; SMN2TAAR1 | |
| SCHEMBL14205398 | 0.81 | TAAR1 (0.61) | ALDH1A1GAATAAR1KDM4ESLC6A4 | |
| SCHEMBL31040515 | 0.81 | GAA (0.64) | ALDH1A1GAAALOX12SMN1; SMN2TAAR1 | |
| SCHEMBL1254037 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GAAALOX12SMN1; SMN2TAAR1 | |
| SCHEMBL30128732 | 0.81 | ALDH1A1 (0.67) | ALDH1A1GAAALOX12SMN1; SMN2TAAR1 | |
| SCHEMBL14612437 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GAAALOX12SMN1; SMN2TAAR1 | |
| SCHEMBL6895229 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GAAALOX12SMN1; SMN2TAAR1 | |
| SCHEMBL8722263 | 0.81 | GAA (0.64) | ALDH1A1GAAALOX12SMN1; SMN2TAAR1 | |
| SCHEMBL7732926 | 0.81 | ALDH1A1 (0.67) | ALDH1A1GAAALOX12SMN1; SMN2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2023-06-01 | — | — | US | disclosed |
| US-20200297726-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2020-09-24 | — | — | US | disclosed |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2017-10-05 | — | — | US | disclosed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9585883-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-03-07 | — | — | US | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | ALDH1A1 1806/4885GAA 352/4885ALOX12 840/4885 |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | ALDH1A1 2806/4885GAA 602/4885ALOX12 4583/4885 |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | ALDH1A1 1556/4885GAA 1172/4885ALOX12 3538/4885 |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | ALDH1A1 1556/4885GAA 1172/4885ALOX12 3538/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | ALDH1A1 1806/4885GAA 352/4885ALOX12 840/4885 |
| US-20200297726-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | ALDH1A1 1556/4885GAA 1172/4885ALOX12 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.